Back to discover
Disease
Non-Muscle Invasive Bladder Neoplasms
Late-stage therapeutic developmentEmerging research
1
Publications
5
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Clinical trial2026-08-06Status changed to Active, not recruiting · ClinicalTrials.gov
Advances in diagnosis and treatment of bladder cancer.
Research2024-02-12BMJ (Clinical research ed.)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 5 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder Cancer
- Q1 2028Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer
- Q2 2028A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
- Q4 203017000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
- Q3 2031A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20282026-08-28
Upcoming trial readoutHigh impact
Results expected Q4 20302026-07-07
Clinical MilestonesViewHide
Results expected
- 2026-08-28A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR AlterationsResults expected Q2 2028
- 2026-08-06A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder CancerResults expected Q1 2027
- 2026-07-0717000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)Results expected Q4 2030
- 2026-07-02A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)Results expected Q3 2031
- 2026-06-05Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder CancerResults expected Q1 2028
Activity timeline5
- 2026-08-28ClinicalA Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR AlterationsResults expected Q2 2028
- 2026-08-06ClinicalA Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) to Determine the Feasibility and Safety of Intratumoral Injection With or Without Intramural Injection in Subjects With Bladder CancerResults expected Q1 2027
- 2026-07-07Clinical17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)Results expected Q4 2030
- 2026-07-02ClinicalA Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)Results expected Q3 2031
- 2026-06-05ClinicalPhase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder CancerResults expected Q1 2028
Clinical trials
The current development programme across all trial phases.
Clinical programme
5
5
2
0
Late-stage studies
Recruiting
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Major themes2
- Non-Muscle Invasive Bladder Neoplasms1
- Urinary Bladder Neoplasms1
Leading journals1
- BMJ (Clinical research ed.)1
Leading researchers4
- Cheng L1
- Cookson MS1
- Guercio BJ1
- Lopez-Beltran A1
Affiliations (unnormalised)6
- Brown University.1
- Department of Pathology and Laboratory Medicine1
- James P. Wilmot Cancer Institute1
- Legorreta Cancer Center1
- University of Cordoba Medical School1
- University of Oklahoma Health Sciences Center and the Stephenson Cancer Center1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A urothelial carcinoma found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.